Eli Lilly’s Foundayo obesity pill eases sleep apnea in late-stage trial, paving way for approval
Summary
Eli Lilly announced positive results from a late-stage clinical trial evaluating its experimental oral treatment for sleep apnea in adults struggling with obesity. The pharmaceutical company intends to submit an application for regulatory approval in the United States before the conclusion of the current year.
Lilly plans to file by the end of the year for U.S. approval of the daily pill for moderate-to-severe obstructive sleep apnea in adults with obesity.
Source: Read the full story at US Top News and Analysis
Disclaimer: This content is for informational and educational purposes only and is not financial, investment or trading advice. Tech & Money Press is not a registered investment adviser or broker-dealer. Trading stocks, options and crypto involves substantial risk, including the loss of your entire investment. Do your own research and consult a licensed professional before making any financial decision. The authors may hold positions in the securities mentioned. News summaries are written with AI assistance from the original publisher's report and may contain errors; always check the original source. Full disclaimer.